Exhibit 99.1
Eclipsys Releases Financial Results for Quarter Ended June 30, 2008
ATLANTA--(BUSINESS WIRE)--Eclipsys Corporation® (NASDAQ: ECLP), The Outcomes Company®, today released results for the quarter ended June 30, 2008.
Second-Quarter Results
Revenues for the quarter ended June 30, 2008 were $132.1 million, compared with revenues of $119.0 million for the quarter ended June 30, 2007, an increase of approximately 11 percent.
Non-GAAP Results
Non-GAAP net income for the quarter was $13.2 million, or $0.24 per diluted share, compared to non-GAAP net income of $9.7 million, or $0.18 per diluted share for the second quarter in 2007. This represents a 33 percent growth in non-GAAP EPS year over year. Non-GAAP net income excludes stock-based compensation expense and certain other items incurred in the quarter that the company does not consider to be indicative of its ongoing business as follows:
· Expense of $4.1 million, or $0.08 per diluted share for stock-based compensation.
· Insurance recoveries of $658,000, or $0.01 per diluted share from the previously disclosed derivative litigation, the settlement of which is pending final court approval.
· Gain of $1.2 million, or $0.02 per diluted share, resulting from the achievement of certain post-closing milestones associated with the December 2007 sale of the Clinical Practice Model Resource Center business.
· Costs of $1.3 million, or $0.02 per diluted share associated with completing the relocation of the corporate headquarters from Boca Raton, FL to Atlanta, GA.
· Expense of $1.1 million or $0.02 per diluted share for amortization of intangible assets associated with the February 2008 acquisition of EPSi.
GAAP Results
On a GAAP basis, net income for the second quarter of 2008 was $8.5 million, or $0.16 per share on a diluted basis, compared to net income of $5.7 million, or $0.11 per share on a diluted basis in the second quarter of 2007. This represents a net income increase of 49 percent and per share increase of 45 percent.
Cash Flows
The company’s operating cash flows for the six months ending June 30, 2008 were $6.6 million, a decrease of $10.2 million compared to six months ended June 30, 2007. Eclipsys ended the quarter with $61.7 million in cash and marketable securities, as well as $111.4 million in long-term investments.
The following table summarizes (unaudited) select financial data:
In thousands, except per share data | In thousands, except per share data | ||||||||||||||||||||||||
Three months ended June 30 | Six months ended June 30 | ||||||||||||||||||||||||
(unaudited) | (unaudited) | ||||||||||||||||||||||||
2008 | 2007 | $ Change | % Change | 2008 | 2007 | $ Change | % Change | ||||||||||||||||||
Revenues | $ | 132,142 | $ | 119,019 | $ | 13,123 | 11 | % | $ | 256,522 | $ | 232,049 | $ | 24,473 | 11 | % | |||||||||
GAAP Results: | |||||||||||||||||||||||||
Net income | $ | 8,511 | $ | 5,694 | $ | 2,817 | 49 | % | $ | 8,800 | $ | 8,095 | $ | 705 | 9 | % | |||||||||
Earnings per common share, diluted | $ | 0.16 | $ | 0.11 | $ | 0.05 | 45 | % | $ | 0.16 | $ | 0.15 | $ | 0.01 | 7 | % | |||||||||
Non-GAAP Results: | |||||||||||||||||||||||||
Net income(a)
| $ | 13,154 | $ | 9,679 | $ | 3,475 | 36 | % | $ | 21,268 | $ | 15,850 | $ | 5,418 | 34 | % | |||||||||
Earnings per common share, diluted(a) | $ | 0.24 | $ | 0.18 | $ | 0.06 | 33 | % | $ | 0.39 | $ | 0.30 | $ | 0.09 | 30 | % | |||||||||
(a) A reconciliation of GAAP to non-GAAP results is included in the attached table. |
“For the second quarter, I am very pleased with Eclipsys’ revenue and EPS growth as well as the expansion of our margins. In addition, we are making great progress with Sunrise Clinical Manager™ 5.0 with several clients now live and operational,” said R. Andrew Eckert, Eclipsys president and chief executive officer. “Eclipsys’ proven ability to help healthcare organizations improve clinical and financial outcomes in an increasingly complex reimbursement and regulatory environment has significantly improved our competitive position and ability to win new business. Additionally, the EPSi acquisition continues to exceed our expectations as we won several new deals this quarter and have built a substantial pipeline.”
Added Eckert, “The agreement we signed with Barbara Ann Karmanos Cancer Institute in the second quarter was a great win for Eclipsys as it demonstrates trust in our ability to not only successfully implement our clinical and financial solutions, but also to manage an entire IT operation.”
Investor Teleconference July 30
Eclipsys senior executives will discuss the results on a teleconference for investors scheduled for 4:30 p.m. Eastern time on July 30. Persons interested in participating in the teleconference should call (800) 230-1096 approximately 15 minutes before the conference call is slated to begin. For listen-only mode, participants can go to www.eclipsys.com prior to the conference call to register and download the necessary audio software.
About two hours after its completion, an audio replay of the call will be available on www.eclipsys.com for approximately 48 hours.
Non-GAAP Measures
The financial results reported in this press release have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). In addition to the GAAP results, the company has provided net income and earnings per share information on a non-GAAP basis for the three and six month periods ended June 30, 2008 and for the three and six month periods ended June 30, 2007 to exclude non-cash stock-based compensation expenses and certain items incurred that the company does not consider to be indicative of its ongoing business, as listed on the attached GAAP to non-GAAP tables. These non-GAAP financial measures should not be considered a substitute for, or superior to, any measure derived in accordance with GAAP. These non-GAAP financial measures may also be inconsistent with the manner in which similar measures are derived or used by other companies. Internally, management uses this non-GAAP information for forecasting and to help make management decisions, as an indicator of business performance, and to evaluate management’s effectiveness and help determine bonuses for management and others.
The economic substance of omitting non-cash stock-based compensation expense in presenting non-GAAP earnings derives from providing investors with consistent measures of performance both before and after including non-cash stock-based compensation charges. The economic substance of omitting the other items incurred that the company does not consider to be indicative of its ongoing business derives from the fact that episodic charges of these kind make it more difficult to compare operating results of different periods, not all of which include such gains and/or charges. However, the omission of non-cash stock-based compensation expense may mask an economic cost incurred by the company in connection with stock-based compensation, and the omission of the charges related to the company’s other non-GAAP adjustments may mask actual and expected future cash expenditures associated with such matters. Management compensates for these limitations by using both the GAAP and non-GAAP measures.
Management believes that the non-GAAP financial measures provided, when considered in conjunction with comparable GAAP financial measures, facilitate the understanding and evaluation of the company’s operating performance and future prospects, as well as comparisons of the company’s results with its prior period results that did not include these gains and/or charges, and with results of other companies on a more consistent basis. For example, omitting the stock-based compensation expense facilitates review by the majority of the company’s analysts, who model the company’s earnings excluding stock-based compensation charges.
The company has provided reconciling tables attached to this release.
About Eclipsys
Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and access management software, clinical content and professional services that help healthcare organizations improve clinical, financial, operational and client satisfaction outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.
Special Note
Statements in this news release or the investor call referenced herein concerning the company’s sales, marketing and operational initiatives; future financial results, operating performance, and development efforts; and the benefits provided by Eclipsys software and services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Future performance expectations are predicated upon achievement of various sales and performance targets that may be difficult to meet. Sales may be slower than expected due to market conditions, competition, and other factors. Costs may be greater than anticipated due to the potential need to increase spending to ensure performance in accordance with commitments to clients and other factors. Software development may take longer and cost more than expected, and incorporation of anticipated features and functionality may be delayed, due to various factors including programming and integration challenges and resource constraints. The market is highly competitive. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software, implementation or consulting services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and clients can terminate contracts, assess penalties or reduce contract scope under certain circumstances. More information about company risks is available in recent Form 10-K and other filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Clinical Manager is a trademark of Eclipsys Corporation.
Eclipsys Corporation | |||||||||||||||||||||||||||||||
Non-GAAP Income Statements | |||||||||||||||||||||||||||||||
(in thousands, except per share amouts) | |||||||||||||||||||||||||||||||
Non-GAAP | Non-GAAP | Non-GAAP | Non-GAAP | ||||||||||||||||||||||||||||
Three Months Ended June 30, 2008 | Three Months Ended June 30, 2007 | $ Change | % Change | Year-to-date June 30, 2008 | Year-to-date June 30, 2007 | $ Change | % Change | ||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||
Systems and services | $ | 126,308 | $ | 114,266 | $ | 12,042 | 10.5 | % | $ | 245,446 | $ | 223,449 | $ | 21,997 | 9.8 | % | |||||||||||||||
Hardware | 5,834 | 4,753 | 1,081 | 22.7 | % | 11,076 | 8,600 | 2,476 | 28.8 | % | |||||||||||||||||||||
Total revenues | 132,142 | 119,019 | 13,123 | 11.0 | % | 256,522 | 232,049 | 24,473 | 10.5 | % | |||||||||||||||||||||
Cost and expenses: | |||||||||||||||||||||||||||||||
Costs of systems and services | 67,413 | 66,456 | 957 | 1.4 | % | 133,072 | 129,873 | 3,199 | 2.5 | % | |||||||||||||||||||||
Costs of hardware | 3,615 | 3,737 | (122 | ) | -3.3 | % | 7,951 | 6,651 | 1,300 | 19.5 | % | ||||||||||||||||||||
Sales and marketing | 20,916 | 17,191 | 3,725 | 21.7 | % | 40,242 | 34,639 | 5,603 | 16.2 | % | |||||||||||||||||||||
Research and development | 15,465 | 13,226 | 2,239 | 16.9 | % | 32,158 | 26,955 | 5,203 | 19.3 | % | |||||||||||||||||||||
General and administrative | 7,051 | 6,003 | 1,048 | 17.5 | % | 14,879 | 12,410 | 2,469 | 19.9 | % | |||||||||||||||||||||
Depreciation and amortization | 4,619 | 4,296 | 323 | 7.5 | % | 8,961 | 8,735 | 226 | 2.6 | % | |||||||||||||||||||||
In-process research and development charge | - | - | - | (a)N/M | - | - | - | (a)N/M | |||||||||||||||||||||||
Total costs and expenses | 119,079 | 110,909 | 8,170 | 7.4 | % | 237,263 | 219,263 | 18,000 | 8.2 | % | |||||||||||||||||||||
Income (loss) from operations | 13,063 | 8,110 | 4,953 | 61.1 | % | 19,259 | 12,786 | 6,473 | 50.6 | % | |||||||||||||||||||||
Gain (loss) on sale of assets | - | - | - | (a)N/M | 33 | - | 33 | (a)N/M | |||||||||||||||||||||||
Interest income, net | 828 | 1,588 | (760 | ) | -47.9 | % | 2,947 | 3,102 | (155 | ) | -5.0 | % | |||||||||||||||||||
Income (loss) before income taxes | 13,891 | 9,698 | 4,193 | 43.2 | % | 22,239 | 15,888 | 6,351 | 40.0 | % | |||||||||||||||||||||
Provision for income taxes | 737 | 19 | 718 | (a)N/M | 971 | 38 | 933 | (a)N/M | |||||||||||||||||||||||
Net income (loss)
| $ | 13,154 | $ | 9,679 | $ | 3,475 | 35.9 | % | $ | 21,268 | $ | 15,850 | $ | 5,418 | 34.2 | % | |||||||||||||||
Net income (loss) per share: | |||||||||||||||||||||||||||||||
Basic net income (loss) per common share | $ | 0.25 | $ | 0.18 | $ | 0.07 | 38.9 | % | $ | 0.40 | $ | 0.30 | $ | 0.10 | 33.3 | % | |||||||||||||||
Diluted net income (loss) per common share | $ | 0.24 | $ | 0.18 | $ | 0.06 | 33.3 | % | $ | 0.39 | $ | 0.30 | $ | 0.09 | 30.0 | % | |||||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||||||||||
Basic | 53,657 | 52,596 | 1,061 | 2.0 | % | 53,595 | 52,471 | 1,124 | 2.1 | % | |||||||||||||||||||||
Diluted | 54,570 | 53,737 | 833 | 1.6 | % | 54,592 | 53,629 | 963 | 1.8 | % | |||||||||||||||||||||
(a) Not Meaningful |
Eclipsys Corporation | ||||||||||||||||||||||||||||||||
GAAP Income Statements (Unaudited) | ||||||||||||||||||||||||||||||||
(in thousands, except per share amouts) | ||||||||||||||||||||||||||||||||
GAAP | GAAP | GAAP | GAAP | |||||||||||||||||||||||||||||
Three Months Ended June 30, 2008 | Three Months Ended June 30, 2007 | $ Change | % Change | Year-to-date June 30, 2008 | Year-to-date June 30, 2007 | $ Change | % Change | |||||||||||||||||||||||||
Revenues: | ||||||||||||||||||||||||||||||||
Systems and services | $ | 126,308 | $ | 114,266 | $ | 12,042 | 10.5 | % | $ | 245,446 | $ | 223,449 | $ | 21,997 | 9.8 | % | ||||||||||||||||
Hardware | 5,834 | 4,753 | 1,081 | 22.7 | % | 11,076 | 8,600 | 2,476 | 28.8 | % | ||||||||||||||||||||||
Total revenues | 132,142 | 119,019 | 13,123 | 11.0 | % | 256,522 | 232,049 | 24,473 | 10.5 | % | ||||||||||||||||||||||
Cost and expenses: | ||||||||||||||||||||||||||||||||
Costs of systems and services | 69,316 | 67,555 | 1,761 | 2.6 | % | 136,876 | 132,048 | 4,828 | 3.7 | % | ||||||||||||||||||||||
Costs of hardware | 3,615 | 3,737 | (122 | ) | -3.3 | % | 7,951 | 6,651 | 1,300 | 19.5 | % | |||||||||||||||||||||
Sales and marketing | 22,781 | 17,901 | 4,880 | 27.3 | % | 43,652 | 36,319 | 7,333 | 20.2 | % | ||||||||||||||||||||||
Research and development | 15,753 | 13,799 | 1,954 | 14.2 | % | 32,907 | 28,057 | 4,850 | 17.3 | % | ||||||||||||||||||||||
General and administrative | 7,713 | 7,606 | 107 | 1.4 | % | 18,676 | 15,208 | 3,468 | 22.8 | % | ||||||||||||||||||||||
Depreciation and amortization | 5,740 | 4,296 | 1,444 | 33.6 | % | 10,506 | 8,735 | 1,771 | 20.3 | % | ||||||||||||||||||||||
In-process research and development charge | - | - | - | (a)N/M
| 850 | - | 850 | (a)N/M
| ||||||||||||||||||||||||
Total costs and expenses | 124,918 | 114,894 | 10,024 | 8.7 | % | 251,418 | 227,018 | 24,400 | 10.7 | % | ||||||||||||||||||||||
Income (loss) from operations | 7,224 | 4,125 | 3,099 | 75.1 | % | 5,104 | 5,031 | 73 | 1.5 | % | ||||||||||||||||||||||
Gain/(loss) on sale of assets | 1,451 | - | 1,451 | (a)N/M | 3,515 | - | 3,515 | (a)N/M | ||||||||||||||||||||||||
Interest income, net | 828 | 1,588 | (760 | ) | -47.9 | % | 2,947 | 3,102 | (155 | ) | -5.0 | % | ||||||||||||||||||||
Income (loss) before income taxes | 9,503 | 5,713 | 3,790 | 66.3 | % | 11,566 | 8,133 | 3,433 | 42.2 | % | ||||||||||||||||||||||
Provision for income taxes | 992 | 19 | 973 | (a)N/M
| 2,766 | 38 | 2,728 | (a)N/M
| ||||||||||||||||||||||||
Net income (loss) | $ | 8,511 | $ | 5,694 | $ | 2,817 | 49.5 | % | $ | 8,800 | $ | 8,095 | $ | 705 | 8.7 | % | ||||||||||||||||
Net income (loss) per share: | ||||||||||||||||||||||||||||||||
Basic net income (loss) per common share | $ | 0.16 | $ | 0.11 | $ | 0.05 | 45.5 | % | $ | 0.16 | $ | 0.15 | $ | 0.01 | 6.7 | % | ||||||||||||||||
Diluted net income (loss) per common share | $ | 0.16 | $ | 0.11 | $ | 0.05 | 45.5 | % | $ | 0.16 | $ | 0.15 | $ | 0.01 | 6.7 | % | ||||||||||||||||
Weighted average common shares outstanding: | ||||||||||||||||||||||||||||||||
Basic | 53,657 | 52,596 | 1,061 | 2.0 | % | 53,595 | 52,471 | 1,124 | 2.1 | % | ||||||||||||||||||||||
Diluted | 54,570 | 53,737 | 833 | 1.6 | % | 54,592 | 53,629 | 963 | 1.8 | % | ||||||||||||||||||||||
(a) Not Meaningful |
ECLIPSYS CORPORATION AND SUBSIDIARIES | ||||||||||
Consolidated Balance Sheets | ||||||||||
(in thousands, except share and per share amounts) | ||||||||||
June 30, | December 31, | |||||||||
2008 | 2007 | |||||||||
(Unaudited) | ||||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash | $ | 61,520 | $ | 22,510 | ||||||
Marketable securities | 155 | 168,925 | ||||||||
Accounts receivable, net of allowance for doubtful accounts of $4,532 and $4,240, respectively | 117,591 | 99,260 | ||||||||
Prepaid expenses | 28,890 | 27,289 | ||||||||
Deferred tax asset | 8,387 | 7,524 | ||||||||
Other current assets | 6,862 | 1,759 | ||||||||
Total current assets | 223,405 | 327,267 | ||||||||
Long-term investments | 111,427 | - | ||||||||
Property and equipment, net | 49,788 | 45,657 | ||||||||
Capitalized software development costs, net | 36,183 | 38,206 | ||||||||
Acquired technology, net | 12,536 | 594 | ||||||||
Intangible assets, net | 6,214 | 1,376 | ||||||||
Deferred tax asset | 36,321 | 31,187 | ||||||||
Goodwill | 39,055 | 7,772 | ||||||||
Other assets | 11,564 | 13,374 | ||||||||
Total assets | $ | 526,493 | $ | 465,433 | ||||||
Liabilities and Stockholders’ Equity | ||||||||||
Current liabilities: | ||||||||||
Deferred revenue | $ | 99,666 | $ | 105,115 | ||||||
Accounts payable | 20,939 | 11,679 | ||||||||
Accrued compensation costs | 17,655 | 24,473 | ||||||||
Notes payable | 50,000 | - | ||||||||
Deferred tax liability | 2,013 | 1,777 | ||||||||
Other current liabilities | 15,949 | 19,381 | ||||||||
Total current liabilities | 206,222 | 162,425 | ||||||||
Deferred revenue | 5,300 | 9,860 | ||||||||
Deferred tax liability | 37,363 | 31,235 | ||||||||
Other long-term liabilities | 6,836 | 3,899 | ||||||||
Total liabilities | 255,721 | 207,419 | ||||||||
Stockholders’ equity: | ||||||||||
Common stock, $0.01 par value, 200,000,000 shares authorized; issued and outstanding, 54,369,132 and 53,806,742, respectively | 544 | 538 | ||||||||
Additional paid-in capital | 528,912 | 519,112 | ||||||||
Accumulated deficit | (255,419 | ) | (264,218 | ) | ||||||
Accumulated other comprehensive income | (3,265 | ) | 2,582 | |||||||
Total stockholders’ equity | 270,772 | 258,014 | ||||||||
Total liabilities and stockholders’ equity | $ | 526,493 | $ | 465,433 |
ECLIPSYS CORPORATION AND SUBSIDIARIES | |||||||||||
Consolidated Statements of Cash Flows (Unaudited) | |||||||||||
(in thousands) | |||||||||||
For the Six Months Ended June 30, | |||||||||||
2008 | 2007 | ||||||||||
Operating activities: | |||||||||||
Net income | $ | 8,800 | $ | 8,095 | |||||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 20,551 | 19,263 | |||||||||
Provision for bad debt | 1,400 | 900 | |||||||||
In-process research and development charge | 850 | - | |||||||||
Deferred income taxes | 367 | 38 | |||||||||
Gain on sale of marketable securities | - | (10 | ) | ||||||||
Stock compensation expense | 7,466 | 5,547 | |||||||||
Gain on sale of assets | (3,515 | ) | - | ||||||||
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions: | |||||||||||
Accounts receivable | (18,808 | ) | (2,126 | ) | |||||||
Prepaid expenses and other current assets | (4,086 | ) | (9,724 | ) | |||||||
Inventory | - | 946 | |||||||||
Other assets | 1,047 | 26 | |||||||||
Deferred revenue | (8,505 | ) | (7,809 | ) | |||||||
Accrued compensation | (6,707 | ) | 2,394 | ||||||||
Accounts payable and other current liabilities | 3,898 | (859 | ) | ||||||||
Long-term liabilities | 2,938 | 65 | |||||||||
Other reconciling items | 862 | - | |||||||||
Total adjustments | (2,242 | ) | 8,651 | ||||||||
Net cash provided by operating activities | 6,558 | 16,746 | |||||||||
Investing activities: | |||||||||||
Purchases of property and equipment | (13,315 | ) | (8,425 | ) | |||||||
Purchase of marketable securities | (102,000 | ) | (52,945 | ) | |||||||
Proceeds from sales of marketable securities | 153,641 | 37,844 | |||||||||
Proceeds from sale of assets | 698 | - | |||||||||
Capitalized software development costs | (6,941 | ) | (9,825 | ) | |||||||
Restricted Cash | - | (1,969 | ) | ||||||||
Earnout out on disposition | 2,582 | - | |||||||||
Cash paid for acquisitions, net of cash acquired | (54,370 | ) | (686 | ) | |||||||
Net cash used in investing activities | (19,705 | ) | (36,006 | ) | |||||||
Financing activities: | |||||||||||
Proceeds from stock options exercised | 2,439 | 7,497 | |||||||||
Proceeds from employee stock purchase plan | 375 | - | |||||||||
Cash paid for debt issuance costs | (421 | ) | - | ||||||||
Repayment of secured financing | (45,000 | ) | - | ||||||||
Proceeds from secured financing | 95,000 | - | |||||||||
Net cash provided by financing activities | 52,393 | 7,497 | |||||||||
Effect of exchange rates on cash and cash equivalents | (236 | ) | 403 | ||||||||
Net increase (decrease) in cash and cash equivalents | 39,010 | (11,360 | ) | ||||||||
Cash and cash equivalents — beginning of period | 22,510 | 41,264 | |||||||||
Cash and cash equivalents — end of period | $ | 61,520 | $ | 29,904 |
Eclipsys Corporation | |||||||||||||||||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Pro Forma Results | |||||||||||||||||||||||||||||||||
(in thousands, except per share amounts) | |||||||||||||||||||||||||||||||||
GAAP | Non-GAAP | ||||||||||||||||||||||||||||||||
Three Months | Stock-based comp expense (1) | Derivative Litigation (2) | EPSI (3) | Gain on sale of assets (4) | Headquarter Relocation (5) | Three Months | |||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||
Systems and services | $ | 126,308 | $ | 126,308 | |||||||||||||||||||||||||||||
Hardware | 5,834 | 5,834 | |||||||||||||||||||||||||||||||
Total revenues | 132,142 | - | - | - | - | - | 132,142 | ||||||||||||||||||||||||||
Cost and expenses: | |||||||||||||||||||||||||||||||||
Costs of systems and services | 69,316 | (1,777 | ) | (126 | ) | 67,413 | |||||||||||||||||||||||||||
Costs of hardware | 3,615 | 3,615 | |||||||||||||||||||||||||||||||
Sales and marketing | 22,781 | (1,488 | ) | (377 | ) | 20,916 | |||||||||||||||||||||||||||
Research and development | 15,753 | (288 | ) | 15,465 | |||||||||||||||||||||||||||||
General and administrative | 7,713 | (566 | ) | 658 | (754 | ) | 7,051 | ||||||||||||||||||||||||||
Depreciation and amortization | 5,740 | (1,121 | ) | 4,619 | |||||||||||||||||||||||||||||
In-process research and development charge | - | - | |||||||||||||||||||||||||||||||
Total costs and expenses | 124,918 | (4,119 | ) | 658 | (1,121 | ) | - | (1,257 | ) | 119,079 | |||||||||||||||||||||||
Income (loss) from operations | 7,224 | 4,119 | (658 | ) | 1,121 | 1,257 | 13,063 | ||||||||||||||||||||||||||
Gain/(loss) on sale of assets | 1,451 | (1,451 | ) | - | |||||||||||||||||||||||||||||
Interest income, net | 828 | 828 | |||||||||||||||||||||||||||||||
Income (loss) before income taxes | 9,503 | 4,119 | (658 | ) | 1,121 | (1,451 | ) | 1,257 | 13,891 | ||||||||||||||||||||||||
Provision for income taxes | 992 | - | - | - | (255 | ) | 737 | ||||||||||||||||||||||||||
Net income (loss) | $ | 8,511 | $ | 4,119 | $ | (658 | ) | $ | 1,121 | $ | (1,196 | ) | $ | 1,257 | $ | 13,154 | |||||||||||||||||
Net income (loss) per share: | |||||||||||||||||||||||||||||||||
Basic net income (loss) per common share | $ | 0.16 | $ | 0.08 | $ | (0.01 | ) | $ | 0.02 | $ | (0.02 | ) | $ | 0.02 | $ | 0.25 | |||||||||||||||||
Diluted net income (loss) per common share | $ | 0.16 | $ | 0.08 | $ | (0.01 | ) | $ | 0.02 | $ | (0.02 | ) | $ | 0.02 | $ | 0.24 | |||||||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||||||||||||
Basic | 53,657 | 53,657 | 53,657 | 53,657 | 53,657 | 53,657 | 53,657 | ||||||||||||||||||||||||||
Diluted | 54,570 | 54,570 | 54,570 | 54,570 | 54,570 | 54,570 | 54,570 | ||||||||||||||||||||||||||
1 | Represents stock-based compensation expense. | ||||||||||||||||||||||||||||||||
2 | This reduction in general and administrative expenses is associated with insurance recoveries related to the previously disclosed derivative litigation, the settlement of which is pending final court approval. | ||||||||||||||||||||||||||||||||
3 | This expense is the amortization of intangible assets associated with the February 2008 acquisition of EPSi. | ||||||||||||||||||||||||||||||||
4 | This gain resulted from the achievement of certain post-closing milestones associated with the December 2007 sale of the Clinical Practice Model Resource Center business. | ||||||||||||||||||||||||||||||||
5 | This cost was related primarily to amounts incurred to relocate the corporate headquarters from Boca Raton to Atlanta. These include salaries and benefits associated with termination of employees not relocating and other administrative costs associated with the move. |
Eclipsys Corporation | ||||||||||||||||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Pro Forma Results | ||||||||||||||||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||||||||||||||
GAAP | Non-GAAP | |||||||||||||||||||||||||||||||
Year-to-date June 30, 2008 (Unaudited) | Stock-based comp expense (1) | Derivative Litigation (2) | EPSI (3) | Gain on sale of assets (4) | Headquarter Relocation (5) | Tax Provision (6) | Year-to-date June 30, 2008 | |||||||||||||||||||||||||
Revenues: | ||||||||||||||||||||||||||||||||
Systems and services | $ | 245,446 | $ | 245,446 | ||||||||||||||||||||||||||||
Hardware | 11,076 | 11,076 | ||||||||||||||||||||||||||||||
Total revenues | 256,522 | - | - | - | - | - | - | 256,522 | ||||||||||||||||||||||||
Cost and expenses: | ||||||||||||||||||||||||||||||||
Costs of systems and services | 136,876 | (3,385 | ) | (419 | ) | 133,072 | ||||||||||||||||||||||||||
Costs of hardware | 7,951 | - | 7,951 | |||||||||||||||||||||||||||||
Sales and marketing | 43,652 | (2,585 | ) | (825 | ) | 40,242 | ||||||||||||||||||||||||||
Research and development | 32,907 | (590 | ) | (159 | ) | 32,158 | ||||||||||||||||||||||||||
General and administrative | 18,676 | (907 | ) | (1,353 | ) | (1,537 | ) | 14,879 | ||||||||||||||||||||||||
Depreciation and amortization | 10,506 | (1,545 | ) | 8,961 | ||||||||||||||||||||||||||||
In-process research and development charge | 850 | (850 | ) | - | ||||||||||||||||||||||||||||
Total costs and expenses | 251,418 | (7,467 | ) | (1,353 | ) | (2,395 | ) | - | (2,940 | ) | - | 237,263 | ||||||||||||||||||||
Income (loss) from operations | 5,104 | 7,467 | 1,353 | 2,395 | 2,940 | 19,259 | ||||||||||||||||||||||||||
Gain/(loss) on sale of assets | 3,515 | (3,482 | ) | 33 | ||||||||||||||||||||||||||||
Interest income, net | 2,947 | 2,947 | ||||||||||||||||||||||||||||||
Income (loss) before income taxes | 11,566 | 7,467 | 1,353 | 2,395 | (3,482 | ) | 2,940 | - | 22,239 | |||||||||||||||||||||||
Provision for income taxes | 2,766 | - | - | - | (255 | ) | (1,540 | ) | 971 | |||||||||||||||||||||||
Net income (loss) | $ | 8,800 | $ | 7,467 | $ | 1,353 | $ | 2,395 | $ | (3,227 | ) | $ | 2,940 | $ | 1,540 | $ | 21,268 | |||||||||||||||
Net income (loss) per share: | ||||||||||||||||||||||||||||||||
Basic net income (loss) per common share | $ | 0.16 | $ | 0.14 | $ | 0.03 | $ | 0.04 | $ | (0.06 | ) | $ | 0.05 | $ | 0.03 | $ | 0.40 | |||||||||||||||
Diluted net income (loss) per common share | $ | 0.16 | $ | 0.14 | $ | 0.02 | $ | 0.04 | $ | (0.06 | ) | $ | 0.05 | $ | 0.03 | $ | 0.39 | |||||||||||||||
Weighted average common shares outstanding: | ||||||||||||||||||||||||||||||||
Basic | 53,595 | 53,595 | 53,595 | 53,595 | 53,595 | 53,595 | 53,595 | 53,595 | ||||||||||||||||||||||||
Diluted | 54,592 | 54,592 | 54,592 | 54,592 | 54,592 | 54,592 | 54,592 | 54,592 | ||||||||||||||||||||||||
1 | Represents stock-based compensation expense. | |||||||||||||||||||||||||||||||
2 | These charges were incurred as a result of the voluntary stock option review completed in the second quarter 2007 and are related primarily to legal fees associated with the subsequent derivative litigation. These costs are net of insurance recoveries in the second quarter 2008. | |||||||||||||||||||||||||||||||
3 | These amounts relate to a charge of $850 for a write off of in-process research and development and amortization of intangible assets recorded as part of the purchase price allocation of the February 2008 acquisition of EPSi. | |||||||||||||||||||||||||||||||
4 | This gain was recorded in conjunction with contingent consideration earned related to the December 2007 sale of the Clinical Practice Model Resource Center business to Elsevier Inc. | |||||||||||||||||||||||||||||||
5 | This cost was related primarily to amounts incurred to relocate the corporate headquarters from Boca Raton to Atlanta. These include salaries and benefits associated with termination of employees not relocating and other administrative costs associated with the move. | |||||||||||||||||||||||||||||||
6 | FASB Interpretation 48 "Accounting for Uncertainty in Income Taxes" clarifies the criteria for recognizing income tax benefits. This charge was recorded as a result of the review of uncertain state tax positions. |
Eclipsys Corporation | |||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Pro Forma Results | |||||||||||||||||||
(in thousands, except per share amounts) | |||||||||||||||||||
GAAP | Non-GAAP | ||||||||||||||||||
| Voluntary Stock Option review (2) |
| |||||||||||||||||
Three Months Ended | Stock-based comp expense (1) | Three Months Ended June 30, 2007 | |||||||||||||||||
Revenues: | |||||||||||||||||||
Systems and services | $ | 114,266 | $ | 114,266 | |||||||||||||||
Hardware | 4,753 | 4,753 | |||||||||||||||||
Total revenues | 119,019 | - | - | 119,019 | |||||||||||||||
Cost and expenses: | |||||||||||||||||||
Costs of systems and services | 67,555 | (1,099 | ) | 66,456 | |||||||||||||||
Costs of hardware | 3,737 | 3,737 | |||||||||||||||||
Sales and marketing | 17,901 | (710 | ) | 17,191 | |||||||||||||||
Research and development | 13,799 | (573 | ) | 13,226 | |||||||||||||||
General and administrative | 7,606 | (405 | ) | (1,198 | ) | 6,003 | |||||||||||||
Depreciation and amortization | 4,296 | 4,296 | |||||||||||||||||
In-process research and development charge | - | - | |||||||||||||||||
Total costs and expenses | 114,894 | (2,787 | ) | (1,198 | ) | 110,909 | |||||||||||||
Income (loss) from operations | 4,125 | 2,787 | 1,198 | 8,110 | |||||||||||||||
Gain/(loss) on sale of assets | - | - | |||||||||||||||||
Interest income, net | 1,588 | 1,588 | |||||||||||||||||
Income (loss) before income taxes | 5,713 | 2,787 | 1,198 | 9,698 | |||||||||||||||
Provision for income taxes | 19 | 19 | |||||||||||||||||
Net income (loss) | $ | 5,694 | $ | 2,787 | $ | 1,198 | $ | 9,679 | |||||||||||
Net income (loss) per share: | |||||||||||||||||||
Basic net income (loss) per common share | $ | 0.11 | $ | 0.05 | $ | 0.02 | $ | 0.18 | |||||||||||
Diluted net income (loss) per common share | $ | 0.11 | $ | 0.05 | $ | 0.02 | $ | 0.18 | |||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||
Basic | 52,596 | 52,596 | 52,596 | 52,596 | |||||||||||||||
Diluted | 53,737 | 53,737 | 53,737 | 53,737 | |||||||||||||||
1 | Represents stock-based compensation expense. | ||||||||||||||||||
2 | These charges were incurred as a result of the voluntary stock option review completed in the second quarter 2007 and relate to legal and professional fees for analysis completed to conduct the review. |
Eclipsys Corporation | |||||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Pro Forma Results | |||||||||||||||||||||
(in thousands, except per share amounts) | |||||||||||||||||||||
GAAP | Non-GAAP | ||||||||||||||||||||
| Voluntary Stock Option review (2) |
| |||||||||||||||||||
Year-to-date June 30, | Stock-based comp expense (1) | Year-to-date | |||||||||||||||||||
Revenues: | |||||||||||||||||||||
Systems and services | $ | 223,449 | $ | 223,449 | |||||||||||||||||
Hardware | 8,600 | 8,600 | |||||||||||||||||||
Total revenues | 232,049 | - | - | 232,049 | |||||||||||||||||
Cost and expenses: | |||||||||||||||||||||
Costs of systems and services | 132,048 | (2,175 | ) | 129,873 | |||||||||||||||||
Costs of hardware | 6,651 | 6,651 | |||||||||||||||||||
Sales and marketing | 36,319 | (1,680 | ) | 34,639 | |||||||||||||||||
Research and development | 28,057 | (1,102 | ) | 26,955 | |||||||||||||||||
General and administrative | 15,208 | (590 | ) | (2,208 | ) | 12,410 | |||||||||||||||
Depreciation and amortization | 8,735 | 8,735 | |||||||||||||||||||
In-process research and development charge | - | - | |||||||||||||||||||
Total costs and expenses | 227,018 | (5,547 | ) | (2,208 | ) | 219,263 | |||||||||||||||
Income (loss) from operations | 5,031 | 5,547 | 2,208 | 12,786 | |||||||||||||||||
Gain/(loss) on sale of assets | - | - | |||||||||||||||||||
Interest income, net | 3,102 | 3,102 | |||||||||||||||||||
Income (loss) before income taxes | 8,133 | 5,547 | 2,208 | 15,888 | |||||||||||||||||
Provision for income taxes | 38 | 38 | |||||||||||||||||||
Net income (loss) | $ | 8,095 | $ | 5,547 | $ | 2,208 | $ | 15,850 | |||||||||||||
Net income (loss) per share: | |||||||||||||||||||||
Basic net income (loss) per common share | $ | 0.15 | $ | 0.11 | $ | 0.04 | $ | 0.30 | |||||||||||||
Diluted net income (loss) per common share | $ | 0.15 | $ | 0.10 | $ | 0.04 | $ | 0.30 | |||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||
Basic | 52,471 | 52,471 | 52,471 | 52,471 | |||||||||||||||||
Diluted | 53,629 | 53,629 | 53,629 | 53,629 | |||||||||||||||||
1 | Represents stock-based compensation expense. | ||||||||||||||||||||
2 | These charges were incurred as a result of the voluntary stock option review completed in the second quarter 2007 and relate to legal and professional fees for analysis completed to conduct the review. These fees were not excluded from the previously announced Non-GAAP net income of $5.2 million, or $0.10 of earnings per diluted share for the first quarter 2007. |
CONTACT:
Eclipsys
Jason Cigarran, 404-847-5965
Director, Investor Relations
jason.cigarran@eclipsys.com
or
Robert J. Colletti, 404-847-5975
Chief Financial Officer
investor.relations@eclipsys.com